Becton Dickinson Co (BDX) SEC Filing 10-Q Quarterly Report for the period ending Friday, December 31, 2021

SEC Filings

BDX Quarterly Reports

Becton Dickinson Co

CIK: 10795 Ticker: BDX

Exhibit 99.1

1 Becton Drive
Franklin Lakes, NJ 07417


Investors: Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743
Media: Troy Kirkpatrick, VP, Public Relations - 858-617-2361


Revenue of $5.0 billion declined 6.0% as reported and 5.9% on currency-neutral basis, due to a decline in worldwide COVID-only testing revenues to $185 million from $866 million in the prior year
Revenue driven by growth of 8.1% as reported, 8.3% currency-neutral, in base revenues
GAAP diluted EPS of $2.28; adjusted diluted EPS of $3.64
Company raises full year revenue and EPS guidance

FRANKLIN LAKES, NJ (Feb. 3, 2022)
- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal year 2022, which ended December 31, 2021.

“Our first quarter results reflect continued execution of our BD2025 strategy and strong base business performance from all three segments. Through our focused execution we are driving meaningful revenue growth and improving margins, and we remain uniquely positioned to deliver value during an uncertain environment,” said Tom Polen, chairman, CEO and president of BD. “We continue to advance our innovation pipeline and tuck-in M&A strategy, strengthening our leadership position in our durable core and adding transformative solutions to our portfolio. As we look forward, we are confident in our ability to deliver on our commitments and are well-positioned to create long-term growth and value for all our stakeholders.”

Recent Business Highlights

BD continues to advance its innovation-driven growth strategy, tuck-in M&A and ESG initiatives. Recent highlights include:
New BD innovation in flow cytometry: Profiled in cover story of January issue of Science magazine, demonstrating landmark advancement in flow cytometry technology with potential to transform a wide range of disciplines from immunology and genomics research to cell-based therapeutics.
BD Kiestra™ IdentifA: Received 510(k) clearance from the U.S. FDA. Designed to automate the preparation of microbiology bacterial identification testing using smart connected robotics.
BD COR™ MX: Received CE Mark for infectious disease testing and is final module introduced on the BD COR™ System, expanding fully-automated high-throughput molecular diagnostic platform for core labs.
BD Veritor™ At-Home COVID-19 Test: New distribution and retail partners announced.

The following information was filed by Becton Dickinson Co (BDX) on Thursday, February 3, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Becton Dickinson Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Becton Dickinson Co.


Assess how Becton Dickinson Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Becton Dickinson Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools


Learn More
Bullish Bearish Neutral
Filter Sentiment:
Filter Category:
M & A
Filter Subcategory:
Cash Flow
Inside Becton Dickinson Co's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover Page
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income
Condensed Consolidated Statements Of Income
Basis Of Presentation
Benefit Plans
Benefit Plans (Tables)
Benefit Plans - Net Pension And Postretirement Cost (Detail)
Business Restructuring Charges
Business Restructuring Charges (Tables)
Business Restructuring Charges - Summary Of Restructuring Accrual Activity (Detail)
Contingencies (Policies)
Contingencies - Additional Information (Detail)
Debt - Additional Information (Detail)
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities (Tables)
Derivative Instruments And Hedging Activities - Additional Information (Detail)
Derivative Instruments And Hedging Activities - Schedule Of Notional Amounts Of Outstanding Derivative Positions (Detail)
Derivative Instruments And Hedging Activities Disclosure - Gains (Losses) On Net Investment Hedges (Details)
Earnings Per Share
Earnings Per Share (Tables)
Earnings Per Share - Weighted Average Common Shares Used In Computations Of Basic And Diluted Earnings Per Share (Detail)
Financial Instruments And Fair Value Measurements
Financial Instruments And Fair Value Measurements (Tables)
Financial Instruments And Fair Value Measurements - Additional Information (Detail)
Financial Instruments And Fair Value Measurements - Cash And Equivalents And Restricted Cash (Details)
Financial Instruments And Fair Value Measurements - Schedule Of Fair Value, Assets And Liabilities Measured On Recurring Basis (Details)
Financial Instruments And Fair Value Measurements - Transfer Of Financial Assets Accounted For As Sales (Details)
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Additional Information (Detail)
Intangible Assets - Components Of Intangible Assets (Detail)
Intangible Assets - Reconciliation Of Goodwill By Business Segment (Detail)
Revenues - Additional Information (Details)
Segment Data
Segment Data (Tables)
Segment Data - Additional Information (Detail)
Segment Data - Financial Information For Company's Segments (Detail)
Segment Data - Revenues By Geographic Areas (Detail)
Shareholders' Equity
Shareholders' Equity (Tables)
Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components And Changes Of Accumulated Other Comprehensive Income (Loss) (Detail)
Shareholders' Equity - Changes In Certain Components Of Shareholders' Equity (Details)
Ticker: BDX
CIK: 10795
Form Type: 10-Q Quarterly Report
Accession Number: 0000010795-22-000017
Submitted to the SEC: Thu Feb 03 2022 11:38:21 AM EST
Accepted by the SEC: Thu Feb 03 2022
Period: Friday, December 31, 2021
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: